Rich Ml 1
1. Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs
2. Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial
3. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial
4. Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis
5. Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
6. Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs
7. All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings
8. Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis
9. Corrigendum to ‘Culture conversion at six months in patients receiving bedaquiline- and delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis’ International Journal of Infectious Diseases Volume 113S1 (2021) S91-S95 (International Journal of Infectious Diseases (2021) 113(S1) (S91–S95), (S1201971221002939), (10.1016/j.ijid.2021.03.075))
10. Culture conversion at six months in patients receiving bedaquiline- and delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis
11. Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial
12. Safety and Effectiveness of 3 Novel All-Oral Shortened Regimens for Rifampicin- or Multidrug-Resistant Tuberculosis in Kazakhstan
13. Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications
14. Effect of smoking on drug-resistant tuberculosis treatment outcomes and potential mechanistic pathways: a multicountry cohort study
15. Effectiveness of Bedaquiline Use beyond Six Months in Patients with Multidrug-Resistant Tuberculosis
16. Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB
17. Effectiveness of a bedaquiline, linezolid, clofazimine ‘core’ for multidrug-resistant TB
1